All In Biotech

Drug Trial Radar · NCT04709575

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Anti-Bet v 1 Monoclonal Antibodies to Reduce Symptoms of Seasonal Allergic Rhinitis

Last checked: Nov 19, 2026Latest source record: Oct 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 353 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

353

Actual

Start

Jan 14, 2021

Primary completion

Aug 24, 2021

Study completion Aug 24, 2021

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jan 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to assess the reduction of allergic symptoms as measured by combined symptom and medication score (CSMS) during birch pollen season after a single dose of REGN5713-5714-5715 versus placebo.

Conditions

  • Allergic Rhinitis
  • Conjunctivitis

Interventions

  • REGN5713Drug

    Administered subcutaneously

  • REGN5714Drug

    Administered subcutaneously

  • REGN5715Drug

    Administered subcutaneously

  • PlaceboDrug

    Placebo that replaces REGN5713-5714-5715

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Combined Symptom and Medication Score (CSMS) in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus PlaceboTime frame: Until the end of Birch Pollen Season, up to Week 16

Locations

37 sites in 5 countries. Site status is shown where the registry gives one.

  • Regeneron Study Site

    Bangor, Maine

  • Regeneron Study Site

    Baltimore, Maryland

  • Regeneron Study Site

    Plymouth, Minnesota

  • Regeneron Study Site

    Columbia, Missouri

  • Regeneron Study Site

    St Louis, Missouri

  • Regeneron Study Site

    Missoula, Montana

  • Regeneron Study Site

    Verona, New Jersey

  • Regeneron Study Site

    Great Neck, New York

  • Regeneron Study Site

    Cincinnati, Ohio

  • Regeneron Study Site

    Toledo, Ohio

  • Regeneron Study Site

    Portland, Oregon

  • Regeneron Study Site

    Pittsburgh, Pennsylvania

  • Regeneron Study Site

    Lincoln, Rhode Island

  • Regeneron Study Site

    Greenfield, Wisconsin

  • Regeneron Study Site

    Ghent, Oost-Vlaanderen, Belgium

  • Regeneron Study Site

    Leuven, Vlaams Brabant, Belgium

  • Regeneron Study Site

    Québec, Canada

  • Regeneron Study Site

    Kingston, Ontario, Canada

  • Regeneron Study Site

    London, Ontario, Canada

  • Regeneron Study Site

    Ottawa, Ontario, Canada

  • Regeneron Study Site

    Toronto, Ontario, Canada

  • Regeneron Study Site

    Toronto, Ontario, Canada

  • Regeneron Study Site

    Toronto, Ontario, Canada

  • Regeneron Study Site

    Trois-Rivières, Quebec, Canada

  • Regeneron Study Site

    Hvidovre, Capital, Denmark

  • Regeneron Study Site

    Hellerup, Copenhagen Surroundings, Denmark

  • Regeneron Study Site

    Vejle, South Jutland, Denmark

  • Regeneron Study Site

    Berlin, Germany

  • Regeneron Study Site

    Berlin, Germany

  • Regeneron Study Site

    Hamburg, Germany

  • Regeneron Study Site

    Heidelberg, Baden-Wurttemberg, Germany

  • Regeneron Study Site

    Stuttgart, Baden-Wurttemberg, Germany

  • Regeneron Study Site

    Dreieich, Hesse, Germany

  • Regeneron Study Site

    Wiesbaden, Hesse, Germany

  • Regeneron Study Site

    Duisburg, North Rhine-Westphalia, Germany

  • Regeneron Study Site

    Düsseldorf, North Rhine-Westphalia, Germany

  • Regeneron Study Site

    Dresden, Saxony, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.